Want to see STXS full AI Analyst Report?
STXS Stock Chart & Stats
$1.33
$0.00(0.00%)
At close: 4:00 PM EDT
$1.33
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1.24 - $3.59
Previous Close$1.33
Volume443.78K
Average Volume (3M)1.04M
Market Cap
$142.29M
Enterprise Value$171.97
Total Cash (Recent Filing)$10.49M
Total Debt (Recent Filing)$5.17M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Nov 05, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding100,202,180
10 Day Avg. Volume1,918,848
30 Day Avg. Volume1,043,755
Financial Highlights & Ratios
PEG Ratio0.55
Price to Book (P/B)11.17
Price to Sales (P/S)6.46
P/FCF Ratio-15.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.00Price Target Upside125.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.19
Revenue Forecast (FY)$39.40M
Bulls Say, Bears Say
Bulls Say
Recurring Revenue GrowthRecurring revenue growth, led by robotically navigated catheters, can make the model more predictable and increase utilization of the installed base. Continued manufacturing expansion could support durable consumables growth and improve revenue quality.
Product And Commercial ExpansionA broader cleared product portfolio expands Stereotaxis’s addressable procedures and customer use cases. Early Synchrony adoption and GenesisX installations could strengthen the platform ecosystem, support system placements and create additional recurring procedure revenue.
Robotics Platform ScaleRobocath adds endovascular robotics capabilities to Stereotaxis’s electrophysiology base, potentially broadening its market and enabling technology synergies. The established hospital footprint and treatment history also provide commercial credibility for future adoption.
Bears Say
Persistent Losses And Cash BurnSustained operating losses and negative free cash flow show that the business is not yet self-funding. Continued cash burn could require external financing, constrain investment capacity and increase dilution risk before the targeted 2027 profitability milestone.
Weak System Revenue And Operating LeverageDependence on infrequent hospital system purchases makes revenue uneven, and the latest decline highlights execution sensitivity. Low system volumes also depress margins, delaying operating leverage and leaving profitability dependent on a sustained recovery in placements.
Manufacturing Capacity ConstraintsSupply constraints prevent the company from fully converting catheter demand into revenue and may frustrate hospitals during adoption. Manufacturing ramp-up and redundancy investments are required, creating execution risk for the recurring-revenue growth plan over coming quarters.
Stereotaxis News
STXS FAQ
What was Stereotaxis’s price range in the past 12 months?
Stereotaxis lowest stock price was $1.24 and its highest was $3.59 in the past 12 months.
What is Stereotaxis’s market cap?
Stereotaxis’s market cap is $142.29M.
When is Stereotaxis’s upcoming earnings report date?
Stereotaxis’s upcoming earnings report date is Nov 05, 2026 which is in 73 days.
How were Stereotaxis’s earnings last quarter?
Stereotaxis released its earnings results on Aug 11, 2026. The company reported -$0.05 earnings per share for the quarter, the consensus estimate of -$0.05 by $0.
Is Stereotaxis overvalued?
According to Wall Street analysts Stereotaxis’s price is currently Undervalued.
Does Stereotaxis pay dividends?
Stereotaxis does not currently pay dividends.
What is Stereotaxis’s EPS estimate?
Stereotaxis’s EPS estimate is -0.05.
How many shares outstanding does Stereotaxis have?
Stereotaxis has 100,202,180 shares outstanding.
What happened to Stereotaxis’s price movement after its last earnings report?
Stereotaxis reported an EPS of -$0.05 in its last earnings report, expectations of -$0.05. Following the earnings report the stock price went down -4.11%.
Which hedge fund is a major shareholder of Stereotaxis?
Currently, no hedge funds are holding shares in STXS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stereotaxis Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (125.56% Upside)
$3.00 (125.56% Upside)
Blogger Sentiment
Neutral
STXS Sentiment 50%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.41%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
35.00%
Trailing 12-Months
Company Description
Stereotaxis
Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. Its products include the Genesis RMN System, the Odyssey Solution, and related devices. The firm also offers the Stereotaxis Imaging Model S x-ray System. The company was founded in June 1990 and is headquartered in St. Louis, MO.
STXS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call contained multiple material positive operational and commercial milestones (FDA clearances, product launches, strong sequential and year‑over‑year growth in robotically navigated catheter revenue, Synchrony early sales, GenesisX installs and OEM compatibility progress, strategic Robocath acquisition) that point to an improving growth trajectory and a clear path to higher recurring revenue and margin expansion. Offsetting these positives are near‑term execution challenges: supply constraints for MAGiC catheters limiting sales, a YoY decline in system revenue driven by a missed system delivery, depressed system margins due to low volumes, ongoing operating losses and negative free cash flow, and transition‑related procedure pressure. Management provided concrete guidance and reiterated a plan to reach cash‑flow profitability in H1 2027, relying on manufacturing ramp and modest capital sales. Overall, the call indicates constructive commercial inflection and credible progress toward profitability, but with meaningful near‑term operational and financial risks that must be managed.View all STXS earnings summariesSTXS Stock 12 Month Forecast
Average Price Target
$3.00
▲(125.56% Upside)
Technical Analysis
Atricure
―
Lemaitre Vascular
―
Merit Medical Systems
―
Staar Surgical
―
Milestone Scientific
―
Ownership Overview
20.29% Insiders
6.40% Mutual Funds
24.39% Other Institutional Investors
42.69% Public Companies and
Individual Investors